Novo NordiskCagriSemaobesity treatmenthealthtech

Novo Nordisk Maintains CagriSema Launch Timeline Despite Device Setback

twixb editorial·May 7, 2026·2 min read·AI-assisted

Key facts

Novo Nordisk's CagriSema launch remains on track for early 2027.
The company discontinued its single-chamber delivery device project.
U.S. approval for CagriSema is expected by the end of 2023.
Novo Nordisk is also advancing zenagamtide for obesity treatment.

What happened

Novo Nordisk, a leading pharmaceutical company, has confirmed that its plans to launch CagriSema, a GLP-1/amylin combination treatment, remain unchanged. This announcement follows the decision to discontinue a project aimed at developing a single-chamber delivery device for the treatment. Despite this setback, the company remains focused on obtaining U.S. approval by the end of 2023 and launching the product in early 2027.

Why it matters

The decision to proceed with the CagriSema launch without the single-chamber device underscores Novo Nordisk's commitment to its dual-chamber system, which may offer distinct advantages in drug delivery. This strategy highlights the company's resilience and adaptability in maintaining its competitive position in the obesity treatment market. Additionally, the progress in phase 3 studies of zenagamtide further demonstrates Novo Nordisk's dedication to addressing the growing demand for effective obesity treatments.